Goldman Sachs Group Inc Uro Gen Pharma Ltd. Transaction History

Goldman Sachs Group Inc

  • $706 Billion
  • Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 290,577 shares of URGN stock, worth $5.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
290,577
Previous 284,334 2.2%
Holding current value
$5.09 Million
Previous $3.14 Million 26.59%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$3.9 - $15.46 $24,347 - $96,516
6,243 Added 2.2%
290,577 $3.98 Million
Q1 2025

May 09, 2025
SELL
$9.27 - $12.13 $307,652 - $402,570
-33,188 Reduced 10.45%
284,334 $3.14 Million
Q4 2024

Feb 11, 2025
BUY
$10.52 - $13.11 $16,463 - $20,517
1,565 Added 0.5%
317,522 $3.38 Million
Q3 2024

Nov 14, 2024
BUY
$12.7 - $17.92 $664,857 - $938,129
52,351 Added 19.86%
315,957 $4.01 Million
Q2 2024

Aug 13, 2024
BUY
$12.72 - $19.2 $1.9 Million - $2.88 Million
149,744 Added 131.51%
263,606 $4.42 Million
Q1 2024

May 15, 2024
SELL
$13.81 - $19.33 $4,957 - $6,939
-359 Reduced 0.31%
113,862 $1.71 Million
Q4 2023

Feb 13, 2024
BUY
$10.87 - $15.93 $658,439 - $964,943
60,574 Added 112.91%
114,221 $1.71 Million
Q3 2023

May 14, 2024
SELL
$8.84 - $22.64 $535,474 - $1.37 Million
-60,574 Reduced 53.03%
53,647 $751,000
Q3 2023

Nov 14, 2023
BUY
$8.84 - $22.64 $196,813 - $504,056
22,264 Added 70.94%
53,647 $751,000
Q2 2023

May 14, 2024
SELL
$8.75 - $14.29 $342,755 - $559,767
-39,172 Reduced 55.52%
31,383 $324,000
Q2 2023

Aug 14, 2023
SELL
$8.75 - $14.29 $342,755 - $559,767
-39,172 Reduced 55.52%
31,383 $324,000
Q1 2023

May 14, 2024
BUY
$7.99 - $11.02 $376,169 - $518,821
47,080 Added 200.55%
70,555 $651,000
Q1 2023

May 11, 2023
BUY
$7.99 - $11.02 $376,169 - $518,821
47,080 Added 200.55%
70,555 $651,000
Q4 2022

May 14, 2024
SELL
$7.55 - $11.96 $883 - $1,399
-117 Reduced 0.5%
23,475 $208,000
Q4 2022

Feb 13, 2023
SELL
$7.55 - $11.96 $883 - $1,399
-117 Reduced 0.5%
23,475 $208,000
Q3 2022

May 14, 2024
SELL
$7.21 - $9.41 $105,576 - $137,790
-14,643 Reduced 38.3%
23,592 $196,000
Q3 2022

Nov 10, 2022
SELL
$7.21 - $9.41 $105,576 - $137,790
-14,643 Reduced 38.3%
23,592 $0
Q2 2022

May 14, 2024
SELL
$5.12 - $8.74 $389,048 - $664,117
-75,986 Reduced 66.53%
38,235 $313,000
Q2 2022

Aug 15, 2022
SELL
$5.12 - $8.74 $58,854 - $100,466
-11,495 Reduced 23.11%
38,235 $313,000
Q1 2022

May 16, 2022
SELL
$5.92 - $9.73 $25,118 - $41,284
-4,243 Reduced 7.86%
49,730 $434,000
Q4 2021

Feb 14, 2022
SELL
$9.03 - $19.13 $28,959 - $61,349
-3,207 Reduced 5.61%
53,973 $513,000
Q3 2021

Nov 10, 2021
BUY
$14.31 - $18.39 $818,245 - $1.05 Million
57,180 New
57,180 $962,000

Others Institutions Holding URGN

# of Institutions
161
Shares Held
39.6M
Call Options Held
2.06M
Put Options Held
717K
View Full List

About UroGen Pharma Ltd.

URGN Quotes by TradingView
  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $398M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email